End-of-day quote
Shanghai S.E.
18:00:00 2024-05-07 EDT
|
5-day change
|
1st Jan Change
|
31.86
CNY
|
+1.27%
|
|
+7.71%
|
-16.33%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,084
|
3,903
|
5,959
|
4,986
|
-
|
-
|
Enterprise Value (EV)
1 |
5,084
|
3,903
|
5,959
|
4,986
|
4,986
|
4,986
|
P/E ratio
|
34.6
x
|
38.4
x
|
39.7
x
|
27.5
x
|
22.2
x
|
17.3
x
|
Yield
|
-
|
-
|
0.79%
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
4.5
x
|
6.48
x
|
4.63
x
|
3.69
x
|
3.21
x
|
EV / Revenue
|
-
|
4.5
x
|
6.48
x
|
4.63
x
|
3.69
x
|
3.21
x
|
EV / EBITDA
|
-
|
25.3
x
|
33.1
x
|
15.5
x
|
14.4
x
|
10.8
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
1.36
x
|
1.99
x
|
1.59
x
|
1.5
x
|
1.41
x
|
Nbr of stocks (in thousands)
|
156,491
|
156,491
|
156,491
|
156,491
|
-
|
-
|
Reference price
2 |
32.49
|
24.94
|
38.08
|
31.86
|
31.86
|
31.86
|
Announcement Date
|
22-04-22
|
23-04-25
|
24-04-08
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
866.7
|
920
|
1,076
|
1,351
|
1,556
|
EBITDA
1 |
-
|
154
|
179.9
|
322.5
|
345.3
|
463.5
|
EBIT
1 |
-
|
140.7
|
143.3
|
245
|
302
|
390.5
|
Operating Margin
|
-
|
16.23%
|
15.57%
|
22.76%
|
22.35%
|
25.1%
|
Earnings before Tax (EBT)
1 |
-
|
140.3
|
122.7
|
239.3
|
296.3
|
386.5
|
Net income
1 |
148
|
101.5
|
150.5
|
185.3
|
229.7
|
295
|
Net margin
|
-
|
11.71%
|
16.35%
|
17.22%
|
17%
|
18.96%
|
EPS
2 |
0.9400
|
0.6500
|
0.9600
|
1.160
|
1.437
|
1.845
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
0.3000
|
-
|
-
|
-
|
Announcement Date
|
22-04-22
|
23-04-25
|
24-04-08
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
3.49%
|
5.03%
|
5.73%
|
6.73%
|
8.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
4.4%
|
5.35%
|
6.3%
|
Assets
1 |
-
|
-
|
-
|
4,212
|
4,293
|
4,683
|
Book Value Per Share
2 |
-
|
18.30
|
19.10
|
20.00
|
21.30
|
22.60
|
Cash Flow per Share
2 |
-
|
0.7500
|
1.250
|
2.970
|
2.100
|
3.080
|
Capex
1 |
-
|
96.3
|
101
|
7.33
|
12.3
|
58.5
|
Capex / Sales
|
-
|
11.11%
|
10.97%
|
0.68%
|
0.91%
|
3.76%
|
Announcement Date
|
22-04-22
|
23-04-25
|
24-04-08
|
-
|
-
|
-
|
Last Close Price
31.86
CNY Average target price
44
CNY Spread / Average Target +38.10% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.33% | 682M | | +32.95% | 700B | | -4.97% | 358B | | +18.83% | 330B | | +3.54% | 287B | | +15.70% | 236B | | +6.68% | 202B | | -9.08% | 197B | | +6.70% | 161B | | -1.81% | 157B |
Other Pharmaceuticals
|